NASDAQ$BEAM
Beam Therapeutics Inc. · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported pipeline updates and first quarter 2023 financial results.
Beam Therapeutics reported its first quarter 2023 financial results, highlighting progress in its BEACON clinical trial, the upcoming BEAM-201 clinical trial, and advancements in its in vivo programs BEAM-301 and BEAM-302. The company's cash position remains strong at $1.1 billion. A net loss of $96.5 million was reported, with R&D expenses increasing to $99.6 million.
- Multiple sites activated and additional patients enrolled in BEACON clinical trial of BEAM-101 for patients with sickle cell disease.
- Gopi Shanker, Ph.D., appointed as Chief Scientific Officer.
- Well-capitalized with $1.1 billion in cash, cash equivalents and marketable securities at the end of the first quarter of 2023.
- Expects to initiate current good manufacturing practice compliant operations at its North Carolina manufacturing facility in late 2023.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$24.2M
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Forward guidance
Beam Therapeutics expects that its cash, cash equivalents and marketable securities as of March 31, 2023, will enable the company to fund its anticipated operating expenses and capital expenditure requirements at least into 2025.
Tailwinds
- Funding directed toward reaching each of the key anticipated milestones for BEAM-101.
- Funding directed toward reaching each of the key anticipated milestones for BEAM-201.
- Funding directed toward reaching each of the key anticipated milestones for BEAM-301.
- Funding directed toward reaching each of the key anticipated milestones for BEAM-302
- Continued investments in platform advancements and manufacturing capabilities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro